Glenmark Pharmaceuticals gets final approval for Indomethacin Extended-Release Capsules

From USFDA

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Indomethacin Extended-Release Capsules USP, 75 mg, the generic version of Indocin SR Extended-Release Capsules, 75 mg of Iroko Pharmaceuticals LLC.

According to IMS Health sales data for the 12 month period ending April 2017, the Indocin SR Extended-Release Capsules, 75 mg market1 achieved annual sales of approximately $6.3 million*.

Powered by Capital Market - Live News